Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of canine visceral Leishmaniasis.

Abstract

BACKGROUND:

A recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi (rLdccys1) was previously shown to induce protective immune responses against murine and canine visceral leishmaniasis. These findings encouraged us to use rLdccys1 in the immunotherapy of naturally infected dogs from Teresina, Piauí, a region of high incidence of visceral leishmaniasis in Brazil.

METHODOLOGY/PRINCIPAL FINDINGS:

Thirty naturally infected mongrel dogs displaying clinical signs of visceral leishmaniasis were randomly divided in three groups: one group received three doses of rLdccys1 in combination with the adjuvant Propionibacterium acnes at one month interval between each dose; a second group received three doses of P. acnes alone; a third group received saline. The main findings were: 1) dogs that received rLdccys1 with P. acnes did not display increase of the following clinical signs: weight loss, alopecia, onychogryphosis, cachexia, anorexia, apathy, skin lesions, hyperkeratosis, ocular secretion, and enlarged lymph nodes; they also exhibited a significant reduction in the spleen parasite load in comparison to the control dogs; 2) rLdccys1-treated dogs exhibited a significant delayed type cutaneous hypersensitivity elicited by the recombinant antigen, as well as high IgG2 serum titers and low IgG1 serum titers; sera from rLdccys1-treated dogs also contained high IFN-γ and low IL-10 concentrations; 3) control dogs exhibited all of the clinical signs of visceral leishmaniasis and had low serum IgG2 and IFN-γ levels and high concentrations of IgG1 and IL-10; 4) all of the dogs treated with rLdccys1 were alive 12 months after treatment, whereas dogs which received either saline or P. acnes alone died within 3 to 7 months.

CONCLUSIONS/SIGNIFICANCE:

These findings illustrate the potential use of rLdccys1 as an additional tool for the immunotherapy of canine visceral leishmaniasis and support further studies designed to improve the efficacy of this recombinant antigen for the treatment of this neglected disease.

• Authors: Josie Haydée Lima Ferreira, Lucilene Dos Santos Silva, Ieda Maria Longo-Maugéri, Simone Katz, Clara Lúcia Barbiéri
• Journal: PLoS neglected tropical diseases (PLoS Negl Trop Dis) Vol. 8 Issue 3 Pg. e2729 (Mar 2014) ISSN: 1935-2735 [Electronic] United States
• PMID: 24625516 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Protozoan
• Cytokines
• Protozoan Proteins
• Recombinant Proteins
• Cysteine Proteases

Topics

• Animals
• Antibodies, Protozoan (blood)
• Brazil
• Cysteine Proteases (genetics, therapeutic use)
• Cytokines (blood)
• Dog Diseases (pathology, therapy)
• Dogs
• Immunotherapy (methods)
• Leishmania infantum (enzymology)
• Leishmaniasis, Visceral (pathology, therapy, veterinary)
• Male
• Mice
• Protozoan Proteins (genetics, therapeutic use)
• Recombinant Proteins (genetics, therapeutic use)
• Survival Analysis
• Treatment Outcome